Press release
Rhinitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharma
"Rhinitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rhinitis Market.
The Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Rhinitis Pipeline Report: https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Rhinitis treatment therapies with a considerable amount of success over the years.
• Rhinitis companies working in the treatment market are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others, are developing therapies for the Rhinitis treatment
• Emerging Rhinitis therapies in the different phases of clinical trials are- EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, Norktotifen, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others are expected to have a significant impact on the Rhinitis market in the coming years.
• In March 2025, The National Allergy Centre of Excellence (NACE), based at Murdoch Children's Research Institute (MCRI), partnered with 17 Australian general practices and allergy clinics to introduce the ARISE trial for adolescents and young adults with hay fever. This study focuses on individuals aged 14 to 29 who experience hay fever, also known as allergic rhinitis.
• In June 2024, Neurent Medical, a company at the forefront of developing non-surgical treatments for chronic inflammatory sinonasal conditions, today announced the publication of positive 12-month outcomes from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology. The study shows that treatment using Neurent Medical's NEUROMARK® radiofrequency (RF) ablation device is safe and leads to sustained, significant improvements in rhinitis symptoms and quality of life throughout the 12-month follow-up period.
Rhinitis Overview
Rhinitis is the inflammation of the inner lining of the nose, often caused by allergens (allergic rhinitis) or infections (non-allergic rhinitis). It leads to symptoms like a runny or stuffy nose, sneezing, itching, and postnasal drip. Common triggers include pollen, dust mites, pet dander, and cold viruses.
Get a Free Sample PDF Report to know more about Rhinitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Rhinitis Drugs Under Different Phases of Clinical Development Include:
• FPP004: Funpep
• INI 2004: Inimmune
• TQC 3564: Chia Tai Tianqing Pharmaceutical Group
• ILT-101: Iltoo Pharma
• IRL201104: Revolo Biotherapeutics
• PA9159: Anhui Palo Alto Pharmaceuticals
• MM09-MG01: Immunotek SL
• AI201901: Abdi Ibrahim Pharmaceuticals
• REGN1908-1909: Regeneron
• Glycopyranosyl lipid adjuvant: Revelation Biosciences
• QX 005N: Qyuns Therapeutics
• HY-083: Hyloris Pharmaceuticals
Rhinitis Route of Administration
Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Rhinitis Molecule Type
Rhinitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Rhinitis Pipeline Therapeutics Assessment
• Rhinitis Assessment by Product Type
• Rhinitis By Stage and Product Type
• Rhinitis Assessment by Route of Administration
• Rhinitis By Stage and Route of Administration
• Rhinitis Assessment by Molecule Type
• Rhinitis by Stage and Molecule Type
DelveInsight's Rhinitis Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Rhinitis product details are provided in the report. Download the Rhinitis pipeline report to learn more about the emerging Rhinitis therapies at:
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Rhinitis Therapeutics Market include:
Key companies developing therapies for Rhinitis are - Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, and others.
Rhinitis Pipeline Analysis:
The Rhinitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rhinitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rhinitis Treatment.
• Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rhinitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Rhinitis drugs and therapies-
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Rhinitis Pipeline Market Drivers
• Increase in the prevalence of various form of Rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Rhinitis Market.
Rhinitis Pipeline Market Barriers
• However, high competition from generic drugs, side-effects associated with the Rhinitis treatment and other factors are creating obstacles in the Rhinitis Market growth.
Scope of Rhinitis Pipeline Drug Insight
• Coverage: Global
• Key Rhinitis Companies: Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others
• Key Rhinitis Therapies: EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, Norktotifen, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others
• Rhinitis Therapeutic Assessment: Rhinitis current marketed and Rhinitis emerging therapies
• Rhinitis Market Dynamics: Rhinitis market drivers and Rhinitis market barriers
Request for Sample PDF Report for Rhinitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Rhinitis Report Introduction
2. Rhinitis Executive Summary
3. Rhinitis Overview
4. Rhinitis- Analytical Perspective In-depth Commercial Assessment
5. Rhinitis Pipeline Therapeutics
6. Rhinitis Late Stage Products (Phase II/III)
7. Rhinitis Mid Stage Products (Phase II)
8. Rhinitis Early Stage Products (Phase I)
9. Rhinitis Preclinical Stage Products
10. Rhinitis Therapeutics Assessment
11. Rhinitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rhinitis Key Companies
14. Rhinitis Key Products
15. Rhinitis Unmet Needs
16 . Rhinitis Market Drivers and Barriers
17. Rhinitis Future Perspectives and Conclusion
18. Rhinitis Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Rhinitis Market https://www.delveinsight.com/report-store/rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rhinitis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Rhinitis Epidemiology https://www.delveinsight.com/report-store/rhinitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rhinitis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Artificial Disc Market: https://www.delveinsight.com/report-store/artificial-disc-market
• Addison's Disease Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Cardiac Monitoring System Market: https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
• Medical Sterilization Equipment Market: https://www.delveinsight.com/report-store/medical-sterilization-equipment-market
• Tinnitus Market: https://www.delveinsight.com/report-store/tinnitus-medical-devices-market
• Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rhinitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharma here
News-ID: 4134173 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Rhinitis
Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth?
Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change…
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the…
Allergic Rhinitis Pipeline involves 32+ key companies continuously working towar …
DelveInsight's 'Allergic Rhinitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Allergic Rhinitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Allergic Rhinitis pipeline domain.
Key Takeaways from the Allergic Rhinitis Pipeline Report
• DelveInsight's Allergic Rhinitis Pipeline analysis depicts a robust space with 32+ active players working to develop 32+ pipeline therapies…
Allergic Rhinitis Market 2018 by Seasonal, Perennial and Non-Allergic Rhinitis T …
The Allergic Rhinitis Treatment Market was valued at US $6.95 billion in the year 2018 and is estimated to reach US $9.66 billion by 2026, at a CAGR of 4.20%.
Allergic Rhinitis is inflammation caused inside the nose by allergen, also called as hay fever. Allergic Rhinitis develops when body’s immune system becomes sensitized and overreacts on exposure to allergens in the environment. It is mostly triggered by outdoor allergens like…
Allergic Rhinitis Market Growing CAGR of 7% with Key Type Seasonal, Perennial an …
Global Allergic Rhinitis Market to Provide Country Level Analysis of the Market with Respect to the Current Market Size and Future Growth prospect. And also Provide Insights about Factors Affecting the Market’s Growth.
Global Allergic Rhinitis Market - Scenario
The common name for allergic rhinitis is hay fever. It is diagnosed when symptoms appear which includes itchy nose, mouth, eyes, throat, skin, as well as other parts of the body; along with…
Allergic Rhinitis Market By Key Type Seasonal, Perennial and Non Allergic Rhinit …
Detail analysis of “Allergic Rhinitis Market” with Respect to Region Specific about Factors Affecting the market’s Growth and Various Analyses which Includes Price Analysis, Supply Chain Analysis, Porters Five Force Analysis on the Basis of Major Players Present in the Market - Forecast till 2022
Global Allergic Rhinitis Market - Scenario
The common name for allergic rhinitis is hay fever. It is diagnosed when symptoms appear which includes itchy nose, mouth, eyes,…
